Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. - Wikidata - wikimedia - TriplyDB

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

http://www.wikidata.org/entity/Q45239493

about

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Calcium and phosphate impact cardiovascular risk.A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.Pharmacotherapy of end-stage renal disease.End-stage renal disease Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients.The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.Lipids, blood pressure, kidney - what was new in 2011?Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006 Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone.Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers.Mechanisms and treatment of extraosseous calcification in chronic kidney disease.Diseases of the parathyroid gland in chronic kidney disease.Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet: will it play a role in reducing cardiovascular events?What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Pharmacological management of cardiorenal syndromes.Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.Vitamin D in chronic kidney disease: is the jury in?Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells.Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.Evolve trial.

P2860

Q24187385-9BF5BE0F-8F67-4980-B8E4-411731558EAB Q27687570-785BDC16-76EF-46D8-BF7F-20C5084B234B Q30421529-92F67CA1-FC47-48E8-88F7-995414D14BD7 Q33531889-10D18FBB-C675-4BDE-8CBB-25DBA81C1A66 Q33850437-6EE82E77-918B-4F93-809E-F89320323A28 Q35115090-9A206512-D273-4A75-8EE6-CD15B7BCF85E Q35219236-450BB6F0-F7B5-4488-A8DA-74F37AF73A4D Q35576108-2313A4EB-B0E4-42FF-90A3-2C7D8ED232E1 Q35576155-491AF15B-0D82-4D68-8034-60A84E02133C Q35658608-07D7DEC7-B1EE-4395-8B72-ABB130B0361D Q35691396-EE39AEFA-0F96-4F1B-ADA3-52AC959252EA Q35983513-7426F3EE-BE56-4013-A952-51A14BCB386C Q36900943-9897D312-220B-47D4-86E6-BD05C5BD3E2F Q37087904-CE9101FA-CD89-4963-B9FD-09805B06EADC Q37228193-3247AF6B-67A6-41AC-8834-4033E956FE6E Q37337334-32880975-1F41-46E7-A2DD-5DB2432F7045 Q37738896-9EC45EFE-4462-4FC6-8672-04E9D02F5888 Q37807991-BC02F3D7-C69A-4D79-8EB4-48DE57851CD8 Q37858461-410D3E1B-ACB1-46E3-96EE-7610629C1F1B Q37871341-41DA192B-FADD-40EA-AEF4-1E59C50A515E Q37902504-E1B8D368-E0D8-47ED-8F87-4CE88BEA3F65 Q37912038-0B1B0BF2-D7E2-4D25-A10B-A892F592200F Q37916534-1663EFEC-4664-4F7F-9EE3-D21A9E56ACC3 Q37993874-DC4CFF63-3C67-4BFB-8070-4985CFAC051A Q38150052-3B9A9C24-0BBA-4BDE-BF23-000E7A880FDE Q39220825-37F77F95-49D7-4089-829C-D4832B0BC4C7 Q39740830-4C2A5D47-2093-4C47-9945-A02A25B7FC58 Q39912396-17C7E6BB-3BE4-410A-A90A-DBAE668885F0 Q41103027-75520B0F-5F6F-4859-996C-EBBE17E10D13 Q41696337-2C3B5161-5C8A-417F-B0F7-367B97FE29C6 Q41850703-178C6FDD-49AC-4DBA-8C7B-35335CFB15F7 Q42683242-0461F162-8461-4D45-9D73-69711262F379 Q43427754-85086DE7-CAA2-4B6F-8937-6F081B9795D4 Q43475954-B8079AF0-0682-4153-A15E-3125EBFF70EF Q43692218-C31A085B-2773-49FD-8A75-0DB7D807D438 Q43826461-68088CF2-3CC9-4AAE-8CE6-E59CB3F07C5C Q44186583-46FEA99D-96BD-4092-8893-A804D72A5A26 Q45002024-F404397A-67C1-45DE-B751-7B765175C5E5 Q46305757-F4A7FC7C-3845-4446-A1B4-8F7A30198582 Q47095498-9F307841-6CCE-4EC2-8842-0FB4DDF3B739

P2860

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

http://www.wikidata.org/entity/Q45239493

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Evaluation of Cinacalcet Thera ...... rationale and design overview.

@en

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events

@nl

type

label

Evaluation of Cinacalcet Thera ...... rationale and design overview.

@en

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events

@nl

prefLabel

Evaluation of Cinacalcet Thera ...... rationale and design overview.

@en

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events

@nl

P1433

Q45239493-96E5F89D-DA68-4FC1-9E43-EE9B915F47A3

P1476

Q45239493-B3EA40EB-8253-435A-990A-7F1B50939EE1

P2093

Q45239493-1CA3B100-7ADF-420E-AEC9-00710545E1FC

Q45239493-52D37334-B276-46A4-92E2-9859735438B9

Q45239493-6CDD88AC-16B9-41C1-A5AF-7C72CCC743D0

Q45239493-73269CCE-3DAE-44CF-A1ED-11757F9058DF

Q45239493-9162C700-3821-4885-8A6E-2AB7C5DB3B53

Q45239493-92B722AB-51BC-479E-A9B6-AE0FA6DA68AF

Q45239493-A13853E9-DE21-4EE0-884F-A156E13BB787

Q45239493-AA8C84E5-A0B4-452B-A96B-2E1CFF434643

Q45239493-B7EECA2A-F514-4D10-9C2E-C3D76F26A5B3

Q45239493-B98DC51F-2FEF-45CD-99C1-F642335037A8

P304

Q45239493-680FC81A-0D9F-45FC-B698-8A0E4F31A7F0

P31

Q45239493-D7945F84-06F4-43C4-BB59-9A92600BC021

P356

Q45239493-341FC04E-C47D-46C0-BF67-1A7E66B6E430

P433

Q45239493-CB1CB4C3-26F9-4783-A99C-F49D5DFBFCB7

P478

Q45239493-7BA28D3C-DB58-4E7D-BFDB-823EDF9C9538

P50

Q45239493-30DA396C-369B-4B1F-8842-0AB9747F91A8

P577

Q45239493-35F1FF9E-B0D3-4433-820B-6EFD0851525C

P5875

Q45239493-8FBCFDCA-20CD-40F1-935F-145E6D25640C

P698

Q45239493-79E6A811-9D5D-4F8E-9FCE-E1AE9BD7E911

P921

Q45239493-1B862944-89B5-4412-B749-830BFE05DCFC

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Evaluation of Cinacalcet Thera ...... rationale and design overview.

@en

P2093

David C Wheeler

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Block

http://www.w3.org/2001/XMLSchema#string

Gerard M London

http://www.w3.org/2001/XMLSchema#string

Glenn M Chertow

http://www.w3.org/2001/XMLSchema#string

Jürgen Floege

http://www.w3.org/2001/XMLSchema#string

Kurt Olson

http://www.w3.org/2001/XMLSchema#string

Lara B Pupim

http://www.w3.org/2001/XMLSchema#string

Moetaz Albizem

http://www.w3.org/2001/XMLSchema#string

Patrick Parfrey

http://www.w3.org/2001/XMLSchema#string

Preston Klassen

http://www.w3.org/2001/XMLSchema#string

P304

898-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04381206

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth W Mahaffey

P577

2007-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6136498

http://www.w3.org/2001/XMLSchema#string

P698

17702710

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio